INTERCEPT
IFCCA is partnering in the groundbreaking
INTERCEPT project!
This multi-million Euro research initiative, funded by the Innovative Health Initiative Joint Undertaking (IHI JU), marks a significant milestone in the fight against Crohn’s disease. By harnessing the power of predictive biomarkers, the project aims to shift Crohn’s from an incurable condition to one that can be effectively managed or even prevented.
-
INTERCEPT is Europe’s first-ever trial using biomarkers to prevent the onset of Crohn’s disease before symptoms develop. With a budget exceeding €38 million over five years, this pioneering initiative brings together 21 collaborative partners from Europe, North America and South Korea. The goal is to validate a panel of biomarkers and develop a blood risk score to identify individuals at high risk of developing Crohn’s disease within five years.
-
As a partner in the INTERCEPT project, IFCCA brings the patient voice to the forefront of this ambitious endeavour. Our involvement ensures that the perspectives and needs of people living with Crohn’s disease and their families are integral to the project’s design and implementation. IFCCA’s commitment to improving the quality of life for those affected by IBD aligns seamlessly with INTERCEPT’s mission to transform the future of Crohn’s disease care.
The INTERCEPT project officially kicks off with a consortium meeting on 19 February 2025 in Berlin, Germany, coinciding with the ECCO Congress. This event will bring together leading researchers, healthcare professionals, and patient advocates to lay the groundwork for this transformative initiative.
Together, we are paving the way for a brighter future for those affected by Crohn’s disease.
INTERCEPT Annual Meeting
On 11–12 December 2025, IFCCA attended the INTERCEPT Annual Meeting in Amsterdam, where Fernanda Salinas and Maria Stella, our EU Project Officers, represented the organisation. Over the two-day event, partners reviewed project progress and aligned strategies on communication, dissemination, and patient engagement.
A key takeaway for IFCCA was the importance of using our communication channels to raise awareness and bring INTERCEPT closer to people living with IBD and their families. By leveraging our platforms, we can help translate complex research into clear and accessible messages, ensuring that information reaches the patient community and strengthens their participation throughout the project. The meeting strengthened collaboration across the consortium and set a clear direction for the next phase of work.
Find out more: www.intercept-ihi.eu
